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Objective: To compare treatment persistence and costs with 3 glaucoma treatment sequences 
(first-line/second-line): latanoprost/latanoprost–timolol (LLT), bimatoprost/bimatoprost–timolol 
(BBT), and travoprost/travoprost–timolol (TTT), derived from the UK General Practitioner 
Research Database (UK-GPRD).
Methods: Patient records referring to ocular hypertension, topical glaucoma treatment, surgery, 
or laser therapy were extracted. Patients prescribed LLT, BBT, or TTT sequences were selected. 
Treatment failure was inferred from glaucoma prescription change (adding or removing a topi-
cal treatment, surgery, or laser therapy). Treatment durations preceding failure were compared 
by applying Wilcoxon’s test to survival curves. Adjustment on confounding variables was 
performed with a Cox model and a propensity score method. Unit costs were estimated from a 
UK National Health Service perspective.
Results: A total of 1592 patients received LLT, 110 BBT, and 114 TTT. Their mean age was 
68 years and the sex ratio almost 1 male:1 female. No significant demographic or comorbidity 
differences were observed between treatment sequences. Treatment persistence at 36 months was 
achieved in 60.0% of LLT, 55.5% of BBT, and 70.3% of TTT patients (P = 0.005). Resources 
consumed and associated monthly costs were significantly less for the TTT group (£17.74) 
compared with BBT (£21.30) and LLT (£22.37) groups.
Conclusion: Analysis of data obtained from the UK-GPRD suggests that the TTT treatment 
sequence achieved longer treatment persistence at lower cost than LLT and BBT.
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Introduction
Primary open angle glaucoma (POAG) is a chronic optic neuropathy that can lead 
to blindness if untreated.1 Its cause is unknown, but raised intraocular pressure 
(IOP) is the main controllable risk factor.2 Among people registered as blind in the 
UK 10% to 11% suffer from glaucoma,3 corresponding approximately to 3400 new 
  registrations per year. The overall prevalence of glaucoma in the population aged 
more than 40 years is approximately 2%,4 amounting to nearly 500,000 people in 
England alone. The rate increases with age, rising to almost 10% of persons older Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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than 75 years. The prevalence may be higher for those with 
a family history of glaucoma, or with African or Caribbean 
black antecedents.5 The most   frequent diagnosis is POAG 
that develops slowly and becomes chronic. However, in about 
50% of cases the   condition remains undiagnosed.6 New cases 
of chronic POAG affecting persons aged 40 to 70 years were 
estimated at 9263 per year in England.7,8 It is estimated that 
3% to 5% of those over 40 years have ocular hypertension, 
which equates to around 1 million people in England.8
Costs of glaucoma in UK working and elderly populations 
total £38 billion per year, with individual lifetime costs up 
to £40,000.9 Observational data indicate a high frequency of 
treatment switches in glaucoma incurring increased costs.10,11 
Although prescribers should consider the daily costs of a 
chosen drug,12 efficacy is also important as it may affect 
total costs, such as ophthalmological visits, laser therapy, 
or surgery.13–15
A recent British recommendation on POAG treatment 
is to ‘offer people newly diagnosed with early or moderate 
POAG, and at risk of significant visual loss in their lifetime, 
treatment with a prostaglandin analogue’.16 Hence, first-line 
treatment should comprise a single drug. Drug combina-
tions are often prescribed after initial treatment failure. 
Accordingly, fixed combinations (eg, a prostaglandin analog 
with timolol) were developed as second-line treatment to 
simplify administration and improve compliance.
Intraocular pressure reduction by prostaglandin ana-
logs, and the greater efficacy of travoprost and bimato-
prost, compared with latanoprost, have been demonstrated 
by meta-analysis.17 However, because effectiveness in 
everyday practice does not necessarily reproduce the close 
follow-up of randomized clinical trials, a survey of field 
observations might help public health decision commit-
tees. Previous observational surveys by Denis et al have 
shown better first-line IOP control with travoprost than 
with latanoprost, and better second-line control with a 
travoprost and timolol fixed combination than with a 
latanoprost and timolol fixed combination.18,19 Also a 
discrete event simulation model showed that time elaps-
ing before switching to third-line treatment was longer 
after travoprost/travoprost–timolol than latanoprost/
latanoprost–timolol,20 when the probability of treatment 
sequence switching was determined by extrapolation from 
2 randomized clinical trials.21,22
Since health authorities increasingly require documen-
tation on effectiveness based on daily prescription data,23 
patients’ medical records are a valuable source of informa-
tion to compare everyday treatment strategies. This approach 
has already been applied to glaucoma treatment and the 
  outcomes are often referred to as ‘persistence’ or ‘adherence’ 
to treatment.24–27
The United Kingdom General Practitioner Research 
Database (UK-GPRD) collects medical information reported 
by a representative sample of general practitioners (GPs).28 
Specialized data on glaucoma are available because GPs 
serve as gatekeepers in the UK. The present study searched 
the UK-GPRD to compare the effectiveness and costs of 
3 different treatment sequences in glaucoma patients, each 
sequence retaining its first-line prostaglandin analog in 
its second-line combination with timolol. The objective 
of this analysis was to compare treatment persistence and 
costs for the following 3 treatment sequences: 1) first-line 
latanoprost (Xalatan®; Pfizer Inc, Bridgewater, NJ) with 
second-line latanoprost plus timolol (Xalacom®; Pfizer Inc), 
ie, latanoprost/latanoprost–timolol); 2) first-line bimatoprost 
(Lumigan®; Allergan Inc, Brunswick, NJ) with second-
line bimatoprost plus timolol (Ganfort®; Allergan Inc), ie, 
bimatoprost/bimatoprost–timolol; and 3) first-line travoprost 
(Travatan®; Alcon Inc, Fort Worth, TX) with second-line 
travoprost plus timolol (DuoTrav®; Alcon Inc), ie, travoprost/
travoprost–timolol.
Patients and methods
Data were extracted on primary care patients from the 
world’s largest computerized database, the UK-GPRD, 
which stores anonymous longitudinal data on approximately 
3 million patients treated by UK general practitioners since 
1987. Records include information on age, gender, medi-
cal   diagnosis, prescriptions, clinical events, and hospital 
referrals.
The glaucoma population was identified with terms that 
specified diagnosis, surgical interventions, and drug treat-
ments, as follows:
1.  Glaucoma diagnostic terms included specific   ‘open-angle’ 
and more generic ‘glaucoma’ expressions. Patients were 
excluded when diagnoses specified ‘closed-angle’, 
‘angle closure’, and ‘glaucoma due to other causes’, 
eg, trauma.
2.  Surgery or laser therapy associated with specific glau-
coma terms were flagged, eg, ‘laser trabeculoplasty’ or 
  ‘iridectomy for glaucoma’. Nonspecific interventions were 
excluded, eg, ‘iridectomy’ without a glaucoma term.
3.  Glaucoma drugs were defined by their active con-
stituents as listed in the British National Formulary 
[www.bnf.com]. Both topical and systemic formulations 
were included.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
363
Persistence and cost-effectiveness of three glaucoma treatments
The analysis focused on newly diagnosed patients treated 
for either glaucoma or ocular hypertension. Eligible patients 
were included when they fulfilled the following 3 criteria: 
1) glaucoma diagnosis (as above); 2) follow-up longer than 
6 months; and 3) treatment with one of the following first-line/
second-line treatment sequences: 1) latanoprost/latanoprost–
timolol (LLT); 2) bimatoprost/bimatoprost–timolol (BBT); 
and 3) travoprost/travoprost–timolol (TTT). These treatment 
sequences were the only anti-IOP lowering agents allowed.
Because the UK-GPRD reports mainly incidence rates 
(such as visits, drugs, comorbidity) much data manage-
ment was needed to extrapolate prevalence rates. The fol-
lowing hypotheses and rules were employed: 1) eye and 
general co-morbidities (ICD-10 codes) were extracted 
from the UK-GPRD from the start of glaucoma treatment, 
but were not necessarily present when glaucoma was first 
  diagnosed; 2) treatment failure was defined as a prescription 
change, ie, replacing, discontinuing, or adding medication 
(association) after starting a treatment sequence; 3) patients 
undergoing laser therapy or surgery for glaucoma were also 
regarded as treatment failures; 4) the principal assumption 
was that topical POAG treatment (categorized by product 
name and prescription dates) was prescribed for a maximum 
of 100 days. Because practitioners rarely prescribed more 
than 3 eye-drop bottles (appropriate for 100 days), a treatment 
prescribed twice within 100 days was assumed to have been 
both renewed and continuous; 5) other topical preparations 
prescribed simultaneously during the foregoing periods were 
regarded as supplementary treatments. The last rule consti-
tuted the main evaluation criterion, ie, treatment failure. The 
economic analysis was applied to resource utilization during 
successful treatment as reported in the database.
Statistical analyses were performed with SAS V9.1 soft-
ware (SAS Institute; NC, USA). Treatment sequences were 
compared at baseline with respect to demography, and 
general and eye comorbidities. Continuous variables were 
compared by a t-test when distributions were normal or, 
conversely, by Wilcoxon’s nonparametric test. Discontinuous 
variables were analysed by a Chi-square test or by Fisher’s 
exact permutation test when samples were small. All tests 
were interpreted 2-sided with P = 0.05.
The study analyzed both direct medical costs and the 
consequences of glaucoma medical care from the economic 
perspective of the UK National Health Service. The database 
yielded information on glaucoma resource utilization as 
  follows: 1) laser or surgical treatments, 2) hospitalizations, 
3) medication, 4) medical visits to specialists and GPs, and 
5) prescription renewals by telephone. Consumed items were 
collected for each patient from the first glaucoma prescription 
to the last follow-up day and included medication following 
treatment failures.
Medication costs were taken from the British National 
  Formulary (2008) and did not take drug discounts into 
account.29 Unit costs relating to laser therapy and surgery 
were estimated from Department of Health tariffs.30 Visits 
to   specialists31 and GPs,32 and prescription renewals by 
telephone33 were costed from two Personal Social Services 
Research Unit reports. Results are expressed as GBP, 2008.
Cost consequences of all 3 treatment sequences were 
estimated with and without adjustment and took into account 
duration of follow-up. Adjustment was made by a linear 
regression model.
Results
The UK-GPRD yielded a total of 69,360 glaucoma patients 
including 1816 who received the studied treatment sequences, 
ie, 1592 patients (LLT), 110 (BBT), and 114 (TTT).
Table 1 shows that the mean age of patients was 68 years with 
a sex ratio of approximately 1 male:1 female. No demographic 
differences were observed between treatment sequences. The 
mean follow-up duration was longest for LLT patients, which 
is explained by earlier market access authorization.
Eye and general comorbidity characteristics are shown in 
Tables 2 and 3, respectively. No imbalance of eye comorbidity 
prevalence was observed between the 3 treatment sequences. 
Also, the prevalence rates of various general comorbidities 
were similar for all sequences, apart from less frequent 
vascular disorders in the LLT group (57.9% versus 69.1% 
[BBT] and 68.4% [TTT]).
Percentages of patients remaining under treatment with 
the studied sequences were estimated at different time points 
(Table 4). At 36 months 60.0% of patients continued with the 
LLT sequence, compared with 55.5% with BBT, and 70.3% 
with TTT (Wilcoxon’s test: P = 0.005).
Logistic regression did not identify any potential con-
founding factor that would bias the time-to-failure differ-
ences above. Hence no adjustment was performed. Figure 1 
presents all 3 survival curves.
Table 5 shows average monthly costs of resources con-
sumed with the 3 treatment sequences. The economic analysis 
was applied to resources consumed during treatment and fol-
lowing failure. Treatment failure was experienced by 821 of 
1592 LLT patients (51.6%), 33 of 110 BBT patients (30.0%), 
and 29 of 114 TTT patients (25.4%). An additional treatment 
was prescribed for 40% of the TTT patients and a switch 
for 52%. Laser therapy or surgery was performed on 2% of Clinical Ophthalmology 2011:5
Table 1 Patient characteristics according to treatment sequence
Patient characteristic Latanoprost/latanoprost–
timolol 
n = 1592
Bimatoprost/bimatoprost–
timolol 
n = 110
Travoprost/travoprost–
timolol 
n = 114
P-value
gender
  Male  48.8% 45.5% 50.9% 0.71
  Female 51.2% 54.5% 49.1%
Age (year) 68.3 68.2 68.8 0.95
Time since diagnosis (years) 4.34 4.24 3.57 0.12
Mean duration of follow-up (days) 1584.46 638.19 798.94 ,0.001
Table 2 Ocular comorbidities according to treatment sequence: reported numbers (%)
Comorbidities Latanoprost/latanoprost–
timolol 
n = 1592
Bimatoprost/bimatoprost–
timolol 
n = 110
Travoprost/travoprost–
timolol 
n = 114
P-value
Anterior eye: structural 
change, deposit, or 
degeneration
339 (21.7%) 27 (24.5%) 18 (15.8%) 0.24
Ocular infection, irritation, 
or inflammation
453 (29.0%) 28 (25.5%) 27 (23.7%) 0.37
Ocular injury 13 (0.8%) 0 (0.0%) 0 (0.0%) –
Ocular neuromuscular 
disorders
83 (5.5%) 8 (7.3%) 5 (4.4%) 0.60
Ocular hemorrhage and 
vascular disorders neC
66 (4.2%) 2 (1.8%) 6 (5.3%) 0.39
Vision disorders 290 (18.6%) 19 (17.3%) 17 (14.9%) 0.60
Abbreviation: NEC, not elsewhere classified.
Table 3 general comorbidities according to treatment sequence: reported numbers (%)
Comorbidities Latanoprost/latanoprost–
timolol 
n = 1,592
Bimatoprost/bimatoprost–
timolol 
n = 110
Travoprost/travoprost–
timolol 
n = 114
P-value
Blood and lymphatic 
disorders
190 (12.2%) 13 (11.8%) 15 (13.2%) 0.94
Cardiac disorders 810 (51.9%) 55 (50.0%) 62 (54.4%) 0.80
ear and labyrinth disorders 807 (51.7%) 55 (50.0%) 62 (54.4%) 0.80
endocrine disorders 337 (21.6%) 22 (20.0%) 24 (21.1%) 0.92
gastrointestinal 1072 (68.6%) 70 (63.6%) 84 (73.7%) 0.27
hepatobiliary 92 (5.9%) 6 (5.5%) 5 (4.4%) 0.79
Musculoskeletal and 
Connective tissue disorders
728 (46.6%) 57 (51.8%) 59 (51.8%) 0.35
nervous system disorders 656 (42.0%) 48 (43.6%) 60 (52.6%) 0.08
Psychiatric disorders 129 (8.3%) 10 (9.1%) 10 (8.8%) 0.94
renal and urinary disorders 681 (43.6%) 49 (44.5%) 47 (41.2%) 0.86
respiratory thoracic and 
Mediastinal disorders
655 (41.9%) 47 (42.7%) 51 (44.7%) 0.84
Vascular disorders 905 (57.9%) 76 (69.1%) 78 (68.4%) 0.009
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Table  4  Percentages  of  patients  persisting  with  travoprost/travoprost-timolol,  latanoprost/latanoprost–timolol,  or  bimatoprost/
bimatoprost–timolol as monotherapy, ranked according to treatment duration
Treatment duration Latanoprost/latanoprost– 
timolol 
n = 1,592
Bimatoprost/bimatoprost– 
timolol 
n = 110
Travoprost/travoprost–
timolol 
n = 114
12 months 88.0% 82.5% 92.8%
24 months 73.8% 66.6% 81.7%
36 months 60.0% 55.5% 70.3%
Time to 50% failure incidence rate 48 months 41 months 62 monthsClinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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patients. Average monthly costs of each treatment sequence 
were calculated for the entire observation period with adjust-
ment on follow-up duration. Costs were significantly less 
with TTT than with LLT or BBT. The LLT sequence was 
significantly more costly than TTT or BBT. Most savings 
related to drug costs followed by visits. Adjustment on 
follow-up duration did not alter the results.
Discussion
We extracted information from the UK-GPRD on time elaps-
ing to a third-line glaucoma treatment with 3 prostaglandin 
analogs, prescribed alone (first-line) and combined with 
timolol (second-line) in previously untreated patients pre-
senting with ocular hypertension, POAG, or both conditions. 
In agreement with the literature we defined ‘treatment failure’ 
as the addition or removal of an IOP-lowering medication, or 
an intervention by laser therapy or surgery. Our analysis indi-
cates that the average patient prescribed the TTT sequence 
switched significantly later to a third-line treatment, at lower 
cost, than patients given LLT or BBT. During the 5 years 
following treatment initiation the annual TTT failure rate was 
significantly less than the LLT and BBT rates.
The imbalance between the treatment groups is largely 
due to the fact that latanoprost had access to the market 
several years before the 2 other prostaglandin analogs, in 
monotherapy and as a timolol fixed combination. However, 
no major differences were observed between the 3 groups 
on the collected data, suggesting no major selection bias, 
although the statistical power of our tests was reduced by 
this unbalance. Whatever, we were able to show some dif-
ferences in terms of treatment persistency.
Our retrospective analysis did not find demographic or 
comorbidity differences between treatment groups except 
for vascular disorders, which were less frequent in the LLT 
group. There is no obvious explanation for this imbalance, 
but since it was not associated with time to third-line treat-
ment our conclusions are not altered.
A study of this nature has not been undertaken before. 
However, our results are supported by 2 previous reports. 
Both Netland et al21 and Topouzis et al22 observed trends sug-
gesting better IOP control with travoprost. These results were 
confirmed by a meta-analysis, in which Denis et al showed 
better IOP control with travoprost or bimatoprost compared 
to latanoprost.17 In addition, our analysis reproduces the 
results of a model that extrapolated third-line treatment from 
randomized clinical trials.19
There are several limitations to this study. The main issue 
is a retrospective study design which precludes verification 
of data accuracy, causing internal validity to fall below the 
standard of a randomized clinical trial. Conversely, however, 
the UK health system confers practical advantages with lon-
gitudinal data collection, well-maintained documentation, and 
by limiting a patient’s freedom to consult other physicians. 
Consequently, we were able to identify prior IOP-lowering 
treatment and ensure group comparability with a high degree 
of accuracy. Because reasons for modifying treatments are 
not documented in the UK-GPRD, it was necessary to assume 
that treatment changes were for reasons of tolerance or lack of 
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Figure 1 Time to treatment failure for travoprost/travoprost–timolol, latanoprost/
latanoprost–timolol, and bimatoprost/bimatoprost–timolol (follow-up was censored 
at 65 months).
Table 5 Average monthly glaucoma costs according to treatment sequence ( )
Cost item Latanoprost/latanoprost–
timolol 
n = 1592
Bimatoprost/bimatoprost–
timolol 
n = 110
Travoprost/travoprost–
timolol 
n = 114
P-value
Drugs 16.97 15.52 13.49 ,0.0001
Monthly consultation costs 4.64 5.46 4.15 0.0004
Monthly hospitalization- surgery–laser 
therapy costs
0.77 0.32 0.10 0.26
Monthly total costs following 
inclusion (£)
22.37 21.30 17.74 ,0.0001
Mean daily costs 0.75 0.71 0.59 ,0.0001
Adjusted monthly total costs 22.46a 20.64b 17.21c
Notes: avsb: 0.03; avsc: ,0.0001; bvsc: 0.0004. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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efficacy. Prescription renewals were not explicitly   documented. 
However, as each eye-drop bottle contained enough fluid for 
28 days,34 including extra provision for patients with instillation 
difficulties,35 we fixed the average renewal period empirically 
at 100 days. Sensitivity analyses conducted on this parameter 
demonstrated the robustness of our findings.
Prospective, randomized clinical trials comparing such 
treatment sequences directly are unlikely to be performed 
because the follow-up would be long (at least 3 to 4 years); 
the number of patients needed per sequence to show a small 
difference would be high; the cost of such a trial would be 
significant, making its social utility questionable; and, finally, 
the relevance of such results would probably be challenged 
because prescribing habits might change with the arrival of 
new treatments or new scientific findings during the study. 
Therefore, a retrospective analysis of patients’ medical 
records is a realistic alternative to a randomized clinical trial, 
even though its evidential value is less.
A retrospective analysis of existing data yields effective-
ness estimates that are free of observational bias, although a 
treatment selection bias may occur when treatments are not 
randomized. Since no imbalances were found between the 
3 treatment sequences, we did not have to perform adjustment 
when comparing treatment persistency.
Conclusion
According to UK-GPRD records, patients treated with 
travoprost/travoprost–timolol benefited from longer treat-
ment persistence at costs significantly lower than those of 
latanoprost/latanoprost–timolol (26.1%), or bimatoprost/
bimatoprost–timolol (16.3%). First-line travoprost followed 
by second-line travoprost–timolol is a cost-effective sequence 
in everyday clinical practice.
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